ICHORtec

Executive Summary

ICHORtec GmbH is a Munich-based molecular diagnostics company founded in 2017, specializing in a proprietary Quantum-FMB® platform that measures Gibbs free energy changes during molecular interactions using fluorescence thermodynamics. This innovative technology enables highly precise diagnostic kits and services for infectious disease detection, gene editing verification, and precision medicine. By quantifying binding thermodynamics, ICHORtec's platform offers sensitivity and specificity advantages over conventional methods, potentially improving early diagnosis and treatment monitoring. The company targets a growing market for advanced diagnostics, with applications in both clinical and research settings. While still early-stage and private, ICHORtec has positioned itself as a niche player in the German diagnostics landscape, leveraging its unique thermodynamic approach to differentiate from competitors like PCR or NGS-based tests.

Upcoming Catalysts (preview)

• Q1 2027CE-IVD Marking for Initial Diagnostic Kit60% success
• Q2 2027Strategic Partnership with Diagnostics Distributor50% success
• Q3 2026Series A Funding Round Completion70% success